A61K 2039/6031
Proteins
Official title: {Proteins}
A61K2039/6031 (Proteins) appears on 2,784 US grants and 4,348 published applications in this corpus.
Search patents in A61K- Granted patents
- 2,784
- Published applications
- 4,348
- Assignees
- 1,679
- Inventors
- 6,743
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1977 | 1 | 0 |
| 1978 | 2 | 0 |
| 1979 | 1 | 0 |
| 1980 | 2 | 0 |
| 1981 | 5 | 0 |
| 1982 | 4 | 0 |
| 1983 | 5 | 0 |
| 1984 | 10 | 0 |
| 1985 | 6 | 0 |
| 1986 | 8 | 0 |
| 1987 | 14 | 0 |
| 1988 | 11 | 0 |
| 1989 | 10 | 0 |
| 1990 | 7 | 0 |
| 1991 | 8 | 0 |
| 1992 | 20 | 0 |
| 1993 | 22 | 0 |
| 1994 | 15 | 0 |
| 1995 | 12 | 0 |
| 1996 | 12 | 0 |
| 1997 | 24 | 0 |
| 1998 | 57 | 0 |
| 1999 | 43 | 0 |
| 2000 | 52 | 0 |
| 2001 | 39 | 8 |
| 2002 | 54 | 90 |
| 2003 | 39 | 129 |
| 2004 | 45 | 139 |
| 2005 | 39 | 136 |
| 2006 | 43 | 117 |
| 2007 | 37 | 115 |
| 2008 | 31 | 131 |
| 2009 | 59 | 157 |
| 2010 | 58 | 163 |
| 2011 | 73 | 176 |
| 2012 | 80 | 155 |
| 2013 | 88 | 152 |
| 2014 | 123 | 179 |
| 2015 | 128 | 205 |
| 2016 | 147 | 198 |
| 2017 | 138 | 200 |
| 2018 | 162 | 209 |
| 2019 | 146 | 203 |
| 2020 | 158 | 232 |
| 2021 | 149 | 237 |
| 2022 | 128 | 222 |
| 2023 | 119 | 252 |
| 2024 | 142 | 244 |
| 2025 | 144 | 171 |
| 2026 | 64 | 128 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- A61K 2039/6037Bacterial toxinsIndexing code948
- A61K 2039/6081AlbuminIndexing code504
- A61K 2039/6068Other bacterial proteinsIndexing code368
- A61K 2039/6075Viral proteinsIndexing code314
- A61K 2039/6056AntibodiesIndexing code285
- A61K 2039/605Mhc molecules or ligands thereofIndexing code218
- A61K 2039/6043Heat shock proteinsIndexing code132
- A61K 2039/6062Muramyl peptidesIndexing code9
Recent patents
- Ambient temperature lipid particle storage systems and methods29 Sep 2026US 12,746,281 B2Ambient Biosciences, Inc.
- Multivalent pneumococcal glycoconjugate vaccines containing emerging serotype 24F15 Sep 2026US 12,734,229 B2Inventprise, LLC
- Production of MHC II/CII complexes1 Sep 2026US 12,721,884 B2
- Vaccines against Chlamydia sp25 Aug 2026US 12,714,743 B2Statens Serum Institut
- Method for prevention and treatment of viral disease25 Aug 2026US 12,714,746 B2Morehouse School of Medicine
- Development of carbohydrate-based anti-salmonella vaccines8 Oct 2026US 2026/0306602 A1Board of Trustees of Michigan State University
- Lipid nanoparticles for the prevention of tuberculosis or other mycobacterial infections8 Oct 2026US 2026/0306603 A1Akagera Medicines, Inc.
- Combination Vaccine8 Oct 2026US 2026/0306615 A1Seqirus Inc.
- Vaccine Adjuvants8 Oct 2026US 2026/0306623 A1Seqirus Inc.
- Rhizavidin variants8 Oct 2026US 2026/0308208 A1Affinivax, Inc.
Most cited
By later US patents
- Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity737US 4,554,101 ANew York Blood Center, Inc. · 1985
- Receptor specific transepithelial transport of therapeutics240US 6,485,726 B1Brandeis University · 2002
- Receptor specific transepithelial transport of therapeutics214US 6,030,613 ABrandeis University · 2000
- Immunogenic polysaccharide-protein conjugates208US 4,356,170 ACanadian Patents and Development Limited · 1982
- Receptor specific transepithelial transport of immunogens207US 6,086,875 ABrandeis University · 2000